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Abstract
Background: Extensively drug-resistant Pseudomonas aeruginosa (XDR-PA) isolates are susceptible to only one
or two classes of antibiotics. In 2011–2012, we investigated an outbreak of XDR-PA affecting children with
onco-hematological diseases.
Methods: Outbreak investigation included ascertainment of cases, tracing of intestinal carriers and environmental
surveillance. Contact precautions were adopted for patients with infection or colonization. Isolates were tested for
antimicrobial susceptibility; phenotypic confirmation of carbapenemase production was performed, and
carbapenemase genes were tested by multiplex polymerase-chain-reaction (PCR). Genotypes were determined by
pulsed-field gel electrophoresis (PFGE).
Results: XDR-PA was isolated from 27 patients; 12 had bacteremia, 6 other infections and 9 were colonized. Severe
neutropenia was significantly associated with bacteremia. Bloodstream-infection mortality rate was 67%. All isolates
were resistant to carbapenems, cephalosporins and penicillins + β-lactamase inhibitors. Isolates were susceptible
only to colistin in 22 patients, to colistin and amikacin in 4, and to ciprofloxacin and colistin in 1. PFGE results
identified 6 subtypes of a single genotype, associated with clusters of cases, and 4 sporadic genotypes. Two
sporadic isolates were metallo-β-lactamase producers, negative to PCR. All other isolates were metallo-β-lactamase
producers due to the presence of a VIM carbapenemase. Incidence of XDR-PA infections decreased from 0.72 cases/
1,000 inpatient-days in March 2011-March 2012, to 0.34/1,000 in April-December 2012, after implementation of
active finding of intestinal carriers on all onco-hematological inpatients.
Conclusions: Control measures targeting intestinal carriers are crucial in limiting in-hospital transmission of XDR-PA
polyclonal strains, protecting more vulnerable patients, such as severely neutropenic children, from developing
clinical infections.
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Background
Pseudomonas aeruginosa is one of the leading causes of
nosocomial bloodstream infections and pneumonia [1,2].
The primary site of colonization and a frequent source
of subsequent infection by P. aeruginosa is the gastro-
intestinal tract, where as many as 50% of critically ill
patients are found to be colonized within 3 days of
admission with as many as 30% of strains displaying
antibiotic resistance [3].
Several P. aeruginosa nosocomial outbreaks caused by
patient-to-patient transmission, environmental sources
or contaminated medical devices have been described
[4-6]. Over recent years, nosocomial infections caused by
multi-drug-resistant P. aeruginosa (MDR-PA) have been
reported in adults and children [7-11]. Multi-drug resist-
ance is defined as non-susceptibility to at least one agent
in three or more antimicrobial categories. Extensively
drug-resistant (XDR) bacterial isolates remain susceptible
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to only one or two classes of antimicrobials [12]. To date,
XDR P. aeruginosa (XDR-PA) nosocomial outbreaks have
been described in adults [13,14]. In this article, we report
and characterize an XDR-PA outbreak in a tertiary-care
pediatric hospital in Italy.
Methods
Setting
The Bambino Gesù Children’s Hospital is a tertiary care
hospital in Rome, Italy, with 607 inpatient beds. In 2011,
hospital acute inpatient admissions were 24,449. Hos-
pital patient population includes children at high risk of
acquiring healthcare-associated infections (HAI), such as
pre-term newborns and immunocompromised patients.
In-hospital actions for preventing and controlling HAI
have been implemented over time [15], and in the years
2007–2010 the annual point prevalence of HAI signifi-
cantly decreased from 7.6% to 4.3% (p < 0.001) [15]. In
2011, HAI annual point prevalence was 3.4% (unpub-
lished data). At that time, no active surveillance of MDR
Gram negative intestinal carriers was in place. The De-
partment of Pediatric Hematology/Oncology includes
several wards for inpatient hospitalization, with a total of
54 inpatient beds, and one outpatient clinic.
Case definitions
Patients who had XDR-PA cultured from blood and no
evident site of infection were defined as bacteremia cases.
Other infections caused by XDR-PA were defined accord-
ing to presence of signs and symptoms, and site of isola-
tion [16]. Patients with positive clinical samples from
non-sterile sites without related signs or symptoms of in-
fection were defined as colonized.
Case finding
Microbiological Laboratory results were retrospectively
reviewed to verify if there were patients with XDR-PA
strains isolated prior to September 2011. Since September
2011, the Microbiology Laboratory transmitted by e-mail
to Infection Control Team (ICT) information on all pa-
tients with XDR-PA isolates (patient demographics, ward
of hospitalization, type of biological sample, date of sam-
ple collection). ICT reviewed medical records for patient’s
clinical data (reason for hospital admission, underlying
diseases, signs and symptoms related to XDR-PA infection
and their date of onset, in-hospital patient transfers, status
at hospital discharge). Since October 2011, active tracing
of intestinal carriers was implemented among patients
hospitalized in the same ward and period of time as a pa-
tient with bacteremia or other infections due to XDR-PA.
In March 2012, active tracing of intestinal carriers was ex-
tended to all inpatients admitted to onco-hematology
wards. Stool samples were collected at admission and
once weekly until discharge.
Environmental surveillance
Environmental sampling was performed throughout the
outbreak period. Sterile cotton swabs were used to ob-
tain samples from water outlets, sinks, drains, beds and
surfaces in patient rooms, and surfaces of nurse’s sta-
tions. Samples of tap water were also obtained.
Control measures
Outbreak control measures were based on intensifying
contact precautions with patients with infection or
colonization. Contact precautions required health care
workers to wear a gown and gloves for all interactions
that might involve contact with the patient or poten-
tially contaminated areas in the patient’s environment,
wearing personal protective equipments upon entry in
the room and discarding them before exiting the patient
room. Adherence to antiseptic hand hygiene was also
reinforced, along with cleaning of patient rooms. Hospi-
talized patients were isolated or cohorted; if this was
not possible, a ≥1 meter spatial separation between beds
was requested. Rooms hosting patients subjected to
contact precautions were identified with an alert poster;
parents and caregivers were educated to comply with
contact precautions. Implementation of contact precau-
tions, including identification of patient rooms and docu-
mentation of parents/caregivers education on patient
clinical record was actively verified by ICT. Precautions
were maintained until the patient had three cultures nega-
tive for XDR-PA, or until hospital discharge. Information
on carriage was reported on hospital discharge letter.
Contact precautions were adopted during outpatient visits
of children who were colonized.
Microbiological and molecular biology studies
P. aeruginosa was identified and tested for antimicrobial
susceptibility by Vitek 2 automated systems (bioMérieux,
Marcy l’Etoile, France) using AST-N201 and AST-N203
Gram Negative Susceptibility Card. On the basis of their
resistance phenotype, all P. aeruginosa strains were further
tested, to confirm resistance, with E-Test quantitative
method for the following antimicrobial agents: amikacin,
gentamicin, ceftazidime, ciprofloxacin, colistin, merope-
nem, piperacillin/tazobactam, tobramycin. Results were
interpreted according to breakpoint criteria defined by the
European Committee on Antimicrobial Susceptibility Test-
ing (EUCAST) for clinical susceptibility characterization
[17]. Phenotypic confirmation of the carbapenemase pro-
duction was tested by combined-disc method using a disc
of meropenem (10 μg) (Becton Dickinson, Milan, Italy)
with and without 400 μg phenylboronic acid and with a
disc of meropenem (10 μg) with and without 10 μL 0.1 M
EDTA on Mueller-Hinton agar II (Oxoid, Basingstoke,
UK) [18]. The carbapenemase production was also tested
by using agar tablet/disc diffusion method by the KPC/
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MBL and OXA, 48 Confirm Kit (ROSCO Diagnostica
A/S, Taastrup, Denmark). The presence of carbapenemase
genes (blaVIM, blaIMP, blaOXA-48, blaNDM, blaKPC, blaSPM,
blaBIC, blaSIM, blaGIM, blaDIM, blaAIM) was confirmed by
multiplex Polymerase-chain-reaction (PCR) [19].
To investigate the genetic relationship among the iso-
lates, XDR-PA strains were analyzed by Pulsed-Field Gel
Electrophoresis (PFGE), performed according to the
PulseNet standardised protocol [20], using XbaI as the
restriction enzyme (New England Biolabs, Ipswich, MA).
To avoid degradation of DNA samples, 50 μM thiourea
was added to the running buffer and agarose gel [21].
Salmonella enterica serotype Braenderup H9812 strain
was used as molecular size marker [22]. Dendrogram and
cluster analysis were performed using algorithms avail-
able in the BioNumerics software package v.6.0 (Applied
Maths, Sint-Martens-Latem, Belgium). Percent similar-
ity between different chromosomal fingerprints was
scored by the Dice coefficient. The unweighted pair
group method with arithmetic means (UPGMA), with a
1.00% tolerance limit and 1.00% optimization, was used
to obtain the dendrogram. Isolates with PFGE patterns
differing in one to four restriction fragments (coefficient
of similarity ≥ 90%) were considered to belong to the
same genotype. Subtypes were assigned to isolates dif-
fering by one to four bands (coefficient of similarity ≥
95%) [23].
Ethical considerations
All the laboratory investigations performed to patients
were part of standard care for outbreak investigation
and control. All the data were collected for management
of the outbreak, in accordance with the hospital policy
regarding outbreak investigations approved by the infec-
tion control committee. For these reasons, the approval
of the ethical committee was not deemed necessary.
Results
From March 2011 to December 2012, 27 isolates of
XDR-PA were collected from 27 patients with infection
or colonization. Most patients (20/27; 74.0%) had a
diagnosis of either acute leukemia or lymphoma; their
median age was 12 years (range: 1–27 years), and 59%
were female (Table 1). Among them, there were 12 pa-
tients with bacteremia, 6 patients with other infections
and 9 patients who were colonized. Profound neutro-
penia, defined as <100 white blood cells/μL (WBC/μL),
was significantly more frequent among patients with
bacteremia than among patients with other types of in-
fection or colonization (83% vs 13%; p < 0.001). Eight of
the 12 patients with bacteremia died because of XDR-
PA bloodstream infection (67%). No deaths related to
XDR-PA or within 30 days from laboratory confirmation
occurred in patients with other sites of infection or
colonization.
All isolates from patients with infection or colonization
were resistant to carbapenems, cephalosporins, and peni-
cillins + β-lactamase inhibitors. Isolates from 22 patients
were susceptible only to colistin; isolates were susceptible
to colistin and amikacin in 4 patients, and susceptible to
ciprofloxacin and colistin in 1.
The first in-hospital case occurred in March 2011, in a
4-year-old Italian child affected by acute lymphoblastic
leukemia who had a genital lesion from which XDR-PA
was cultured. Thirteen of the 18 patients (72%) with
bacteremia or infections other than bacteremia occurred
between July 2011 and March 2012, while the majority
of colonized patients were identified from March to
November 2012 (6/9; 67%). Due to their underlying dis-
ease, all patients were admitted to the hospital several
times, either for inpatient care or as outpatients. After
the index case, an epidemiological link was documented
for 23/26 patients, who were visited as outpatients on
the same day (2 patients) or hospitalized in the same
ward and period of time (21 patients). All inpatient
wards were involved.
Incidence of XDR-PA infections decreased from 0.72/
1,000 inpatient days (13 cases; 18,030 inpatient days) in
the period March 2011-March 2012, to 0.34/1,000 in
April-December 2012 (5 cases; 14,839 inpatient days)
after implementation of active surveillance of intestinal
carriage among all inpatients hospitalized in the onco-
hematology wards.
PFGE was performed on 25 isolates from 25 different
patients; isolates from the two remaining patients were
not available for PFGE testing. Results showed that the 25
isolates belonged to 5 different genotypes (A-E) (Figure 1).
A high degree of genetic similarity (≥95%) was ob-
served within and between 6 pattern (A1-A6) in cluster
A. Subtype A1 was the most predominant pattern in-
cluding 9 strains isolated from March 2011 to January
2012 (Figure 2). Subtype A4 was isolated from March to
September 2012 from 6 patients. Subtypes A2, A3, A5
and A6 were isolated from one or two patients. The
remaining 4 isolates (B-E) had different genotypes and
were sporadic. The proportion of cases with bacteremia
and the bloodstream infections mortality rate did not
significantly vary by genotype.
The carbapenemase phenotypic tests on the 25 available
isolates showed that all isolates presented a metallo-β-
lactamase (MBL)-production phenotype. This phenotype
was confirmed by carbapenemase multiplex PCR in all ge-
notypes, except C and E, which were negative by multi-
plex PCR (Table 2).
A total of 35 environmental surveillance samples were
collected (22 in October 2011, 13 in January 2012), none
of which resulted to be positive for XDR-PA.
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Discussion
In Italy, an increase in frequency of bacteremia due to
MDR-PA has been described in pediatric hematology
oncology centers [1]. The outbreak we report, which oc-
curred in children with onco-hematological diseases, is
particularly worrisome, considering that not only bacter-
ial virulence but also a state of profound impairment of
immune defense contribute to both morbidity and mor-
tality. In fact, clinical presentation of XDR-PA was se-
vere: out of 18 infected patients, 12 had bacteremia, and
67% of them died due to XDR-PA bloodstream infec-
tion. The observed mortality rate was higher than that
reported for MDR-PA bacteremia cases in children [1],
but lower than that described in a nosocomial outbreak
of pan-antibiotic-resistant P. aeruginosa [14]. A recent
Spanish study suggested that XDR-PA strains are particu-
larly prone to cause bacteremia, though it was unclear
whether this invasive capacity depended on clonal traits
or on other virulence determinants [24]. As expected, we
observed that severe neutropenia was significantly associ-
ated with XDR-PA bacteremia, compared to other infec-
tions or colonization due to XDR-PA.
Carbapenems are one of the most effective antimicrobial
agents against gram-positive and gram-negative bacteria;
unfortunately pathogens resistant to this antimicrobial
family continue to emerge, due to plasmid or integron-
mediated carbapenemases, efflux systems, reduced porin
expression and increased chromosomal cephalosporinase
activity [25]. All but two XDR-PA strains isolated in this
outbreak were MBL producers, due to the presence of a
blaVIM gene. The first VIM (Verona integron-encoded
metallo-β-lactamase) type MBLs was reported in 1999
in Italy in a P. aeruginosa [26]. At present these en-
zymes are spread through all continents, being also
Table 1 Characteristics of patients with infections or colonization due to XDR P. aeruginosa; Bambino Gesù Children’s
Hospital, 2011–2012 (N: 27)
Bacteremia Other infections Colonization Total
Number of patients 12 6 9 27
N (%) N (%) N (%) N (%)
Age
Median 11.5 15 11 12
Range (2;24) (3;27) (1;16) (1;27)
Gender
Male 4 (33.3%) 2 (33.3%) 5 (55.6%) 11 (40.7%)
Female 8 (66.7%) 4 (66.6%) 4 (44.4%) 16 (59.3%)
Diagnosis
Leukemia/lymphoma 11 (91.7%) 4 (66.6%) 5 (55.6%) 20 (74.1%)
Solid tumor 0 0 1 (11.1%) 1 (3.7%)
Marrow failure 0 1 (16.6%) 0 1 (3.7%)
Inborn error 1 (8.3%) 1 (16.6%) 3 (33.3%) 5 (18.5%)
Chemotherapy
Yes 8 (66.7%) 1 (16.6%) 3 (33.3%) 12 (44.4%)
No 4 (33.3%) 5 (83.3%) 6 (66.7%) 15 (55.6%)
HSCT
Yes 4 (33.3%) 1 (16.6%) 1 (11.1%) 6 (22.2%)
No 8 (66.7%) 5 (83.3%) 8 (88.9%) 21 (77.8%)
Neutropenia (severity)
<100 WBC/mm3 10 (83.3%) 1 (16.6%) 1 (11.1%) 12 (44.4%)
100-500 WBC/mm3 2 (16.7%) 0 0 2 (7.4%)
>500-1000 WBC/mm3 0 0 1 (11.1%) 1 (3.7%)
>1000 WBC/mm3 0 5 (83.3%) 7 (77.8%) 12 (44.4%)
Outcome
Died 8 (66.7%) 0 0 8 (29.6%)
Alive 4 (33.3%) 6 (100%) 9 (100%) 19 (70.4%)
WBC: white blood cells; HSCT: Hematopoietic stem cell transplantation.
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associated with large outbreaks of MDR P. aeruginosa
or Enterobacteriaceae [27,28].
In our study, the genetic relationship among isolates
was investigated by using PFGE analysis, which has been
proven to be a reliable tool for typing P. aeruginosa
strains [3; 13; 14; 29]. As observed in other investigations
[8,9,29], clonal groups and XDR-PA sporadic strains
were identified.
It is likely that the emergence of XDR-PA observed in
our hospital was related to different mechanisms, including
Figure 1 PFGE analysis of P. aeruginosa isolates. Bambino Gesù Children’s Hospital, 2011–2012 (N: 25).
Figure 2 Patients with XDR P. aeruginosa infection or colonization by month of laboratory confirmation and genotype. Bambino Gesù
Children’s Hospital, 2011-2012 (N: 27).
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development of resistance in previously susceptible P. aer-
uginosa isolates, horizontal transfer of MBL genes, and
patient-to-patient transmission.
Under high antimicrobial pressure, there is a risk of
polyclonal emergence of multiple-antibiotic-resistant P.
aeruginosa. Use of broad-spectrum cephalosporins and
of aminoglycosides antibiotics have been documented to
be independent risk factors for spread of MDR-PA [29],
while exposure to fluoroquinolones has been reported to
be associated with XDR-PA bacteremia [24]. Exposure to
antimicrobial agents is a documented risk factor also for
acquired MBL [28]. All children but two we diagnosed
to be affected by XDR-PA bacteremia had been given
ciprofloxacin as medical prophylaxis. Judicious choice of
antimicrobials used for prophylactic courses or empirical
treatment should be emphasized in order to prevent de
novo emergence of XDR-PA strains.
Asymptomatic carriers of MDR-PA play an important
role in long-term in-hospital transmission [30]. Active
surveillance for identification of intestinal carriers of MDR
gram-negative bacteria at hospital admission, followed by
adoption of contact precaution and isolation has been rec-
ommended as a measure for limiting the risk of inter-
personal transmission [31].
Conclusions
In this outbreak, the transmission chain starting from
the first patient, who was diagnosed in March 2011 and
whose XDR-PA isolate belonged to genotype A1, has in-
volved a total of nine patients, over a 10-month period.
The number of patients in other clusters decreased over
time, with six patients for genotype A4, and two cases
for genotype A3 and A5. No secondary cases were ob-
served for four sporadic genotypes. All wards of the
onco-hematological Department were involved; trans-
mission could have occurred through hands of health
care workers, or use of non-critical medical equipments
such as phonendoscopes. Optimal adherence to contact
Table 2 Characteristics of XDR P. aeruginosa isolates; Bambino Gesù Children’s Hospital, 2011–2012 (N: 27)
Patient Id. Month/Year of isolation Site of isolation PFGE Phenotyping Carbapenemases multiplex PCR
1 03/2011 Vaginal swab A1 Metallo-β-lactamase blaVIM
2 07/2011 Blood A1 Metallo-β-lactamase blaVIM
3 08/2011 Blood A1 Metallo-β-lactamase blaVIM
4 09/2011 Blood A1 Metallo-β-lactamase blaVIM
5 09/2011 Blood Not available
6 09/2011 Blood A1 Metallo-β-lactamase blaVIM
7 09/2011 Urine A1 Metallo-β-lactamase blaVIM
8 10/2011 Surgical site C Metallo-β-lactamase Negative
9 10/2011 Stool A1 Metallo-β-lactamase blaVIM
10 12/2011 Blood B Metallo-β-lactamase blaVIM
11 01/2012 Urine A2 Metallo-β-lactamase blaVIM
12 01/2012 Vaginal swab A1 Metallo-β-lactamase blaVIM
13 01/2012 Ocular secretion A1 Metallo-β-lactamase blaVIM
14 02/2012 Blood A3 Metallo-β-lactamase blaVIM
15 03/2012 Blood A4 Metallo-β-lactamase blaVIM
16 03/2012 Stool A4 Metallo-β-lactamase blaVIM
17 05/2012 Blood A4 Metallo-β-lactamase blaVIM
18 05/2012 Blood A4 Metallo-β-lactamase blaVIM
19 06/2012 Blood A6 Metallo-β-lactamase blaVIM
20 06/2012 Surgical site A5 Metallo-β-lactamase blaVIM
21 07/2012 Stool D Metallo-β-lactamase blaVIM
22 08/2012 Stool A4 Metallo-β-lactamase blaVIM
23 09/2012 Tracheal aspirate E Metallo-β-lactamase Negative
24 09/2012 Blood A4 Metallo-β-lactamase blaVIM
25 10/2012 Urine Not available
26 11/2012 Stool A3 Metallo-β-lactamase blaVIM
27 11/2012 Stool A5 Metallo-β-lactamase blaVIM
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precautions is essential to limit the risk of health care
associated transmission of MDR and XDR microorgan-
isms. Since the implementation of active surveillance
aimed at identifying intestinal carriers along with the
adoption of contact precautions, isolation or cohorting
of XDR-PA carriers, incidence of XDR-PA infections
was 2 times lower than that observed prior to implementa-
tion. These findings confirm that adoption of control mea-
sures targeting intestinal carriers should be undertaken in
limiting in-hospital transmission of XDR-PA strains,
protecting more vulnerable patients, such as severely
neutropenic children, from developing clinical infec-
tions, including bacteremia. Italy is one of the European
Countries with the highest proportion of multidrug-
resistant and carbapenemase-producing Enterobacteria-
ceae [32]. Active tracing of fecal carriage should be
recommended for high-risk hospitalized children.
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